ArticleThe American journal of pathology1989
Neuroblastic differentiation potential of the human retinoblastoma cell lines Y-79 and WERI-Rb1 maintained in an organ culture system. An immunohistochemical, electron microscopic, and biochemical study.
Article in The American journal of pathology, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 50 citations in OpenAlex.
- Targeting MYCN Degradation by HLB-0532259 Induces Senescence in Retinoblastoma.Investigative ophthalmology & visual science · 2026Article
- Joint CB1 and NGF Receptor Activation Suppresses TRPM8 Activation in Etoposide-Resistant Retinoblastoma Cells.International journal of molecular sciences · 2024Article
- Efficient assembly of nanopore reads via highly accurate and intact error correction.Nature communications · 2021Article
- Regulated differentiation of WERI-Rb-1 cells into retinal neuron-like cells.International journal of molecular medicine · 2017Article
- An optimized gene transfection system in WERI-Rb1 cells.International journal of molecular medicine · 2017Article
- Tumorspheres but not adherent cells derived from retinoblastoma tumors are of malignant origin.PloS one · 2013Article
- Neuron-associated class III beta-tubulin, tau, and MAP2 in the D-283 Med cell line and in primary explants of human medulloblastoma.The Histochemical journal · 1994Article
- Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma.The British journal of ophthalmology · 1993Review
- A morphological and immunohistochemical study of human retinal pigment epithelial cells, retinal glia, and fibroblasts grown on Gelfoam matrix in an organ culture system. A comparison of structural and nonstructural proteins and their application to cell type identification.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 1993Article
- Immunohistochemical analysis of 61 pituitary adenomas with a monoclonal antibody to the neuron-specific beta-tubulin isotype.Acta neuropathologica · 1993Article
- Expression of developmentally defined retinal phenotypes in the histogenesis of retinoblastoma.The American journal of pathology · 1992Review
- A continuous cell line (KK-2) from a supratentorial primitive neuroectodermal tumor.Acta neuropathologica · 1992Article
- Neuronal and glial properties of a murine transgenic retinoblastoma model.The American journal of pathology · 1991Article
- The pathobiology of salivary gland. I. Growth and development of rat submandibular gland organoids cultured in a collagen gel matrix.Virchows Archiv. A, Pathological anatomy and histopathology · 1991Article
- An immunohistochemical study of neuropeptides and neuronal cytoskeletal proteins in the neuroepithelial component of a spontaneous murine ovarian teratoma. Primitive neuroepithelium displays immunoreactivity for neuropeptides and neuron-associated beta-tubulin isotype.The American journal of pathology · 1989Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The differentiation potential of the human retinoblastoma cell lines Y-79 and WERI-Rb1 was evaluated in vitro for up to 120 days in a matrix system and in rotary suspension for 30 days. Matrix cultures were grown with 10% fetal calf serum (FCS), with and without differentiation-promoting agents. The latter were applied for a total of 5-45 days (usually 30 days) and included 7S nerve growth factor, dibutyryl cyclic AMP, sodium butyrate, retinoic acid, hydrocortisone, and ascorbic acid. Fully defined, serum-free medium and medium containing 5 or 15% FCS were also used for matrix cultures, and medium with 5 or 10% FCS for suspension cultures. By immunoperoxidase (performed on matrix cultures, both untreated and treated for 30 days with differentiation-promoting agents), the cells of both lines were positive for neuron-specific enolase (NSE), microtubule-associated protein 2 (MAP2), class III beta-tubulin (human h beta 4) isotype, and synaptophysin. In addition, the WERI-Rb1 cells expressed 200 kd neurofilament protein (NFP-H) and retinal S-antigen. Both lines were invariably negative for glial fibrillary acidic (GFA) protein, myelin-associated glycoprotein, myelin basic protein, the epitope recognized by the Leu-7 monoclonal antibody, opsin, and hydroxy-indole-O-methyltransferase. In the Y-79 line the presence of NSE and the absence of NF proteins-H, -M and -L, of GFA protein, and of retinal S-antigen were confirmed biochemically. No differentiated features were found by electron microscopy in either line. Thus, in the matrix system employed, both lines exhibited solely a potential for neuroblastic differentiation, which was more advanced in the WERI-Rb1 line, as reflected by the antigenic expression of NFP-H and of retinal S-antigen.
Indexed as
Identifiers
2643884PMC1879546W258538081What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.